News | Stents Drug Eluting | November 03, 2017

Biotronik Orsiro DES Shows Low Five-Year Event Rates

Vascular intervention/five-year results presented at TCT 2017 demonstrate high long-term safety and clinical performance of ultrathin drug-eluting stent

Biotronik Orsiro DES Shows Low Five-Year Event Rates

November 3, 2017 — Biotronik's Orsiro drug-eluting stent (DES) demonstrated high long-term safety and clinical performance according to 60-month follow-up data presented during the 2017 Transcatheter Cardiovascular Therapeutics Annual Conference (TCT 2017), Oct. 29-Nov. 2 in Denver.

Data from the BIOFLOW-II randomized controlled trial was presented in a poster session by Ton Slagboom, M.D., Onze Lieve Vrouwe Gasthuis, Amsterdam, Netherlands, showing a target leisure failure (TLF) rate of 10.4 percent in the Orsiro group and 12.7 percent in the Xience study arm at 60 months (p=0.4728). No definite or probable stent thrombosis occurred during 60 months of follow-up in the Orsiro group (n=268). In the Xience group (n=132), one case of very late definite thrombosis was detected (0.7 percent) at five years.

In addition, data from BIOFLOW-III, a prospective, non-randomized, open-label, all-comers registry was presented in a poster session by Johannes Waltenberger, M.D., professor of cardiology and angiology at University Hospital Münster, Germany. Of an initially enrolled population of 1,356 patients, 898 patients consented for long-term follow-up. Among these patients, there was a follow-up compliance of 90 percent at 60 months. The TLF rate of the full cohort was 9.3 percent at 60 months and definite or probable stent thrombosis occurred in eight cases (0.7 percent, including two very late stent thromboses).

Long-term data for both trials demonstrate that the previously observed low TLF rates at 12 months persisted through the 60-month follow-up. Rates of definite and probable stent thrombosis remained low through 60 months, affirming the safety of the Orsiro stent system in the long term.

"In choosing a permanent implant, clinicians must always consider the long-term impact of their choices; with this data Orsiro joins the limited number of DES with proven favorable outcomes out to five years," commented Slagboom, an investigator in the BIOFLOW-II trial.

The new data presented at TCT 2017 supplements the existing body of evidence supporting the use of the Orsiro DES, with over 32,500 patients enrolled to date in the Orsiro clinical program. This includes the recently reported BIOFLOW-V study data, which showed significantly lower 12-month TLF rates compared to Xience.

For more information:

Related Content

Shockwave Initiates U.S. Pivotal Study for Coronary Intravascular Lithotripsy
News | Cath Lab | January 16, 2019
Shockwave Medical Inc. has initiated its U.S. Food and Drug Administration (FDA) Investigational Device Exemption (IDE...
National Academy of Engineering, Ohio University Award 2019 Russ Prize
News | Cath Lab | January 03, 2019
Ohio University and the National Academy of Engineering announced the 2019 Fritz J. and Dolores H. Russ Prize will be...
Videos | Cath Lab | January 03, 2019
This is walk through inside one of the cardiac hybrid cath labs at the...
Videos | Cath Lab | January 03, 2019
This is the newest cardiac cath lab at the ...
Study Finds Effective Treatment for Coronary Slow Flow
News | Cath Lab | December 27, 2018
Patients who arrive at the hospital with heart-attack-like symptoms have had little recourse for their chest pain if...
Shockwave Announces Collaboration With Abiomed on Physician Training
News | Cath Lab | December 14, 2018
Shockwave Medical announced a new investment and collaboration agreement with Abiomed Inc. As outlined by the agreement...
Sponsored Content | Videos | Cath Lab | October 24, 2018
Michael Flaherty, M.D., discusses a study published in Circulation Research which finds that use of hemodynamic suppo
Philips Showcases Integrated Solutions for Cardiovascular Care at TCT 2018
News | Cath Lab | September 20, 2018
At the Transcatheter Cardiovascular Therapeutics (TCT) annual meeting, Sept. 21–25 in San Diego, Philips is showcasing...
Overlay Init